Artemis Medicare Services has published the audio recording of its earnings conference call for the first quarter of fiscal year 2027 (Q1 FY27). The call, held on August 4, 2026, provided management commentary on the company’s operational and financial performance for the period. This disclosure ensures that all stakeholders, including those unable to attend the live event, have equal access to the detailed discussion regarding the company's recent results.

The release of the audio recording is pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates timely and accurate disclosure of material events to stock exchanges and investors. By making the recording available, the company complies with its regulatory obligations to maintain transparency in its communications with the investing public.

Accessing the Recording

Investors and analysts can listen to the full duration of the earnings call by visiting the company’s official website. The audio file is hosted under the investor relations section, ensuring easy accessibility for anyone seeking deeper insights into the management's perspective on the quarter's performance.

Compliance and Sign-off

The announcement was issued by Poonam Makkar, Company Secretary and Compliance Officer of Artemis Medicare Services Limited. The communication was digitally signed on August 4, 2026, at 14:49:20 +05'30. The notice was simultaneously submitted to both the National Stock Exchange of India Limited and BSE Limited for record-keeping purposes.

What This Means for Investors

While the filing itself does not contain specific financial figures such as revenue or net profit, it serves as a critical resource for investors analyzing the qualitative aspects of the company's performance. The earnings call typically provides context behind the numbers, including strategic initiatives, market conditions, and future outlooks. For a comprehensive analysis of Q1 FY27, investors should combine this audio commentary with the audited financial statements filed separately with the exchanges.

Artemis Medicare Services reported a 48.3% year-on-year increase in consolidated net profit after tax (PAT) to ₹3,144.27 lacs for the quarter ended June 30, 2026 (Q1FY27), driven by robust revenue growth and significant margin expansion. Revenue from operations rose 12.7% to ₹28,732.35 lacs, while the EBITDA margin widened to 21.5% from 19.0% in the corresponding period last year. The strong profitability underscores effective operational leverage as patient volumes and average revenue per occupied bed improved across its flagship facilities. In a separate development, the Board of Directors approved an expansion plan for Tower IV at its Gurugram hospital, adding over 200 beds focused on pediatric and women’s health services.

The results were approved by the Board on August 3, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The unaudited financial statements were reviewed by statutory auditors T R Chadha & Co LLP, who issued an unmodified conclusion under Regulation 33. The consolidated figures include the results of its subsidiary, Artemis Cardiac Care Private Limited, which reported total assets of ₹2,260.47 lacs and net profit of ₹37.75 lacs for the quarter.

Financial Performance Highlights

On a standalone basis, revenue from operations grew 12.9% year-on-year to ₹28,200.97 lacs, with PAT rising 45.0% to ₹3,105.11 lacs. The standalone EBITDA margin improved to 21.6% from 19.1% in Q1FY26. Consolidated total income stood at ₹29,269.74 lacs. Other income declined by 22.4% to ₹537.39 lacs, primarily due to the utilization of International Finance Corporation (IFC) funds towards expansion projects. Finance costs decreased by 12.5% to ₹645.99 lacs, further supporting bottom-line growth.

The following table summarizes the key consolidated financial metrics for Q1FY27:

Operative expenses increased by 6.7% to ₹16,776.44 lacs, while employee benefit expenses rose 11.6% to ₹4,283.64 lacs. The company’s paid-up equity share capital remained unchanged at ₹1,583.06 lacs.

Operational Metrics and Growth Drivers

The flagship hospital in Gurugram demonstrated strong operational health, with inpatient volumes increasing 11.4% to 9,181. Occupancy rates improved to 65.7%, up 443 basis points year-on-year. The Average Revenue Per Occupied Bed (ARPOB) rose 7.4% to ₹85,690, reflecting a high-acuity clinical mix. Average Length of Stay reduced slightly to 3.54 days from 3.67 days, indicating enhanced efficiency.

Revenue from overseas patients increased by 8.6% to ₹7,650.52 lacs, contributing approximately 27.5% to the Gurugram hospital’s revenue. About 60% of total revenue is derived from high-acuity specialties such as oncology, transplants, and robotic surgery. The company has established 14 Centres of Excellence across more than 40 specialties.

Capacity Expansion Roadmap

The Board approved the addition of 200+ beds in Tower IV at the Sector-51, Gurugram facility, dedicated to quaternary pediatric care and advanced gynecology & women’s health services. This expansion aims to address growing demand for specialized neonatal, pediatric intensive care, and high-risk pregnancy management. The project requires an investment of approximately ₹160–180 crore, financed through internal accruals and debt, with completion expected within two years.

Other key initiatives include:

• Raipur Hospital: A 300+ bed super speciality hospital commenced operations in July 2026.
• South Delhi Hospital: An MSA was executed for a 650+ bed facility expected to commence operations by FY29.
• Overseas Operations: The company operates an 80-bed facility in Mauritius and announced a 110-bed facility in FY27.

What the Numbers Show

The divergence between revenue growth (12.7%) and PAT growth (48.3%) highlights significant operating leverage achieved in Q1FY27. The EBITDA margin expansion of 250 basis points suggests that fixed costs are being spread over a larger volume base while variable costs are managed effectively. Despite a decline in other income due to IFC fund utilization for expansion, core operational earnings remained resilient. The strategic focus on high-acuity cases and international patients continues to drive premium ARPOB, supporting long-term value creation.